by Paul McIntosh | Jan 23, 2023 | 2023, In the News
NovaBiotics adds ISO 14001: 2015 and ISO 45001: 2018 accreditations to its integrated quality management system. ISO 14001: 2015 Environmental Management Systems and ISO 45001:2018 Occupational Health & Safety Systems accreditation have now been awarded to...
by Paul McIntosh | Apr 21, 2022 | 2022, Press Releases
New preclinical data further support the application of NM002 as novel anti-inflammatory-antimicrobial intervention in community acquired pneumonia and also data demonstrate the in vitro safety profile, fungal cell specificity and potential of NP339 in respiratory...
by Paul McIntosh | Jan 4, 2022 | 2022, Events
Aberdeen, January 4, 2022 – NovaBiotics Ltd, a privately held clinical stage company developing novel immune based therapies for life-threatening and life-limiting-diseases, today announced that Dr Deborah O’Neil OBE, FRSE, Chief Executive Officer of...
by Paul McIntosh | Dec 8, 2021 | 2021, Press Releases
NovaBiotics’ NM002 (cysteamine bitartrate) Under Investigation in a Phase 3 Study for Community Acquired Pneumonia, Including COVID-19, Influenzas and Bacterial Pneumonias Aberdeen, December 8, 2021. NovaBiotics Ltd, a privately held clinical stage company developing...
by Paul McIntosh | Jul 7, 2021 | 2021, Press Releases
NovaBiotics were highlighted in Jonathan Smith’s article in Labiotech on “Scotland’s Top Ten Biotech Companies to Watch Out For.” Learn more about Scotland’s “thriving life sciences ecosystem” by accessing the article Labiotech Article Scotland’s Top Ten...
Recent Comments